Gastrointestinal Neuroendocrine Tumors¶
Chapter 89 | Part 4: Oncology and Hematology
KEY CLINICAL POINTS¶
- Incidence of neuroendocrine tumors (NETs) has increased 6.4-fold over the past 40 years, with >170,000 prevalent cases in the U.S.
- Somatostatin analogues (octreotide, lanreotide) are first-line for hormone hypersecretion, with 177Lu-DOTA-octreotate showing 65.2% PFS at 20 months in NETTER-1
- Ki-67 index and mitotic count are critical for grading (grade 1: <3% Ki-67, grade 3: >20% Ki-67)
1. DEFINITION & OVERVIEW¶
Neuroendocrine tumors (NETs) are a heterogeneous group of tumors arising from neuroendocrine cells. They are classified as either extrapancreatic (carcinoid tumors) or pancreatic NETs. Functional tumors secrete hormones causing syndromes like carcinoid syndrome, while non-functional tumors are asymptomatic until they cause mass effects.
Table 89-1 Histologic Classification of Neuroendocrine Tumors¶
| CLASSIFICATION | DIFFERENTIATION | GRADE | MITOTIC COUNT | KI-67 |
|---|---|---|---|---|
| Neuroendocrine tumor | Well differentiated | Low grade (grade 1) | <2 per 10 HPF | <3% |
| Neuroendocrine tumor | Well differentiated | Intermediate grade (grade 2) | 2–20 per 10 HPF | 3–20% |
| Neuroendocrine tumor | Well differentiated | High grade (grade 3) | >20 per 10 HPF | >20% |
| Neuroendocrine carcinoma | Poorly differentiated | High grade (grade 3) | >20 per 10 HPF | >20% |
1.1 Histologic Classification¶
NETs are categorized by differentiation and grade (Table 89-1). Well-differentiated tumors (grades 1-2) have low mitotic counts (<20/10 HPF) and Ki-67 <20%. Poorly differentiated tumors (grade 3) have >20 mitoses/10 HPF and Ki-67 >20%.
1.2 Molecular Features¶
Common genetic alterations include MEN1 mutations (44% of sporadic pancreatic NETs), DAXX/ATRX mutations, and mTOR pathway abnormalities. These drive tumorigenesis and influence treatment response.
2. EPIDEMIOLOGY¶
Incidence of NETs has increased 6.4-fold from 1973-2012. Prevalence exceeds 170,000 in the U.S. Risk factors include MEN1 syndrome (40% of patients with pancreatic NETs), von Hippel-Lindau disease, and neurofibromatosis. Environmental factors are less clearly linked.
Table 88-4 Combination Chemotherapy Regimens for Stage IV Pancreatic Cancer¶
| STUDY DESIGN (AUTHOR/REF) | NO. OF PATIENTS | MEDIAN OVERALL SURVIVAL (MONTHS) |
|---|---|---|
| Gemcitabine + erlotinib vs gemcitabine (Moore et al) | 569 | 6.24 vs 5.91 (HR 0.82) |
| FOLFIRINOX vs gemcitabine (Conroy et al) | 342 | 11.1 vs 6.8 (HR 0.57) |
| Nab-paclitaxel + gemcitabine vs gemcitabine (Von Hoff et al) | 861 | 8.5 vs 6.7 (HR 0.72) |
| NALIRIFOX vs nab-paclitaxel + gemcitabine (Wainberg et al) | 770 | 11.1 vs 9.2 (HR 0.83) |
2.1 Demographics¶
Most common in middle-aged adults. Pancreatic NETs are more prevalent in men, while small intestine NETs show equal gender distribution.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Genetic syndromes (MEN1, VHL, NF1) account for ~10-15% of cases. Sporadic tumors involve mutations in MEN1 (44%), DAXX/ATRX, and mTOR pathway. Hormone secretion (serotonin, gastrin, insulin) drives carcinoid syndrome and other paraneoplastic syndromes.
3.1 Molecular Mechanisms¶
DAXX/ATRX mutations disrupt chromatin remodeling, while mTOR pathway activation promotes cell proliferation. Serotonin synthesis via tryptophan hydroxylase drives carcinoid syndrome.
4. CLINICAL FEATURES¶
Functional tumors present with hormone-related syndromes (carcinoid, Zollinger-Ellison, VIPoma). Non-functional tumors cause mass effects (abdominal pain, weight loss). Carcinoid syndrome features flushing, diarrhea, and fibrotic complications.
Table 89-2 Clinical Presentation and Management of Secretory Syndromes¶
| CLINICAL SYMPTOMS AND MANIFESTATIONS | TREATMENT OPTIONS TO CONTROL SECRETORY SYMPTOMS |
|---|---|
| Gastrinoma (gastrinoma triangle): Zollinger-Ellison syndrome (GERD, peptic ulcers, diarrhea) | Proton pump inhibitors, somatostatin analogues |
| Glucagonoma: Necrolytic migratory erythema, glucose intolerance, weight loss | Somatostatin analogues |
| VIPoma: Watery diarrhea, hypokalemia, achlorhydria | Somatostatin analogues |
| ACTHoma: Cushing’s syndrome (hyperglycemia, weight gain, hypokalemia) | Ketoconazole, metyrapone, adrenalectomy |
4.1 Secretory Syndromes¶
Gastrinoma: Zollinger-Ellison syndrome (peptic ulcers, diarrhea). Glucagonoma: necrolytic migratory erythema, diabetes. VIPoma: watery diarrhea, hypokalemia.
5. DIFFERENTIAL DIAGNOSIS¶
Differentiate from other GI tumors (adenocarcinoma, lymphoma) and paraneoplastic syndromes. For carcinoid syndrome, consider mastocytosis and other neuroendocrine tumors.
5.1 Key Differentiators¶
Carcinoid syndrome (flushing, diarrhea) vs. mastocytosis (urticaria, hypotension). Functional pancreatic tumors vs. insulinomas (hypoglycemia).
6. INVESTIGATIONS & DIAGNOSIS¶
Imaging (CT/MRI, somatostatin scintigraphy) and biochemical tests (chromogranin A, 5-HIAA) are critical. Endoscopic ultrasound (EUS) is essential for small tumors. Histopathology confirms grading via Ki-67 and mitotic count.
Table 89-3 Selected Randomized Trials of Therapeutic Agents for Advanced NETs¶
| TUMOR TYPE | NUMBER OF PATIENTS | PROGRESSION-FREE SURVIVAL |
|---|---|---|
| Pancreatic and Extrapancreatic NETs | 204 | 65% vs 33% at 2 years (lanreotide vs placebo) |
| Cabozantinib vs placebo | 298 | 8.5 vs 4 months (epNET); 13.8 vs 4.5 months (pNET) |
| Everolimus vs placebo | 410 | 11 vs 4.6 months (pNET) |
| Sunitinib vs placebo | 171 | 11.4 vs 5.5 months |
| Surufatinib vs placebo | 198 | 9.2 vs 3.8 months |
6.1 Diagnostic Criteria¶
Positive somatostatin receptor imaging (68Ga-DOTATATE PET). Elevated chromogranin A (>200 ng/mL) with negative tumor markers in non-functional tumors.
7. MANAGEMENT & TREATMENT¶
Surgical resection is first-line for localized tumors. Somatostatin analogues (octreotide, lanreotide) control hormone secretion. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTA-octreotate improves PFS. Targeted therapies (everolimus, sunitinib) for advanced disease.
Table 88-4 Combination Chemotherapy Regimens for Stage IV Pancreatic Cancer¶
| STUDY DESIGN (AUTHOR/REF) | NO. OF PATIENTS | MEDIAN OVERALL SURVIVAL (MONTHS) |
|---|---|---|
| Gemcitabine + erlotinib vs gemcitabine (Moore et al) | 569 | 6.24 vs 5.91 (HR 0.82) |
| FOLFIRINOX vs gemcitabine (Conroy et al) | 342 | 11.1 vs 6.8 (HR 0.57) |
| Nab-paclitaxel + gemcitabine vs gemcitabine (Von Hoff et al) | 861 | 8.5 vs 6.7 (HR 0.72) |
| STUDY DESIGN (AUTHOR/REF) | NO. OF PATIENTS | MEDIAN OVERALL SURVIVAL (MONTHS) |
|---|---|---|
| NALIRIFOX vs nab-paclitaxel + gemcitabine (Wainberg et al) | 770 | 11.1 vs 9.2 (HR 0.83) |
7.1 Surgical Options¶
Distal pancreatectomy for pancreatic NETs. Right colectomy for rectal NETs. Endoscopic resection for small (<1 cm) tumors.
7.2 Medical Therapies¶
Somatostatin analogues (octreotide 30 mg monthly), everolimus (10 mg daily), sunitinib (37.5 mg daily). Telotristat ethyl for carcinoid diarrhea.
8. PROGNOSIS & COMPLICATIONS¶
Median survival for well-differentiated NETs exceeds 5 years. Carcinoid heart disease (tricuspid regurgitation) and fibrotic complications from serotonin are major long-term risks. Metastatic disease significantly worsens prognosis.
8.1 Survival Outcomes¶
5-year survival for localized pancreatic NETs: ~90%. Metastatic disease: 2-4 years with optimal therapy. Carcinoid syndrome mortality: 5-10% within 5 years.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid somatostatin analogues in first trimester. Pediatrics: Monitor for MEN1 syndromes. Elderly: Consider reduced-dose chemotherapy. Genetic counseling for familial syndromes (MEN1, VHL).
9.1 Pregnancy¶
Avoid somatostatin analogues in first trimester. Monitor for fetal growth restriction. Consider octreotide in third trimester for tumor control.
10. KEY POINTS & CLINICAL PEARLS¶
- Use 68Ga-DOTATATE PET for tumor localization and grading.
- Ki-67 index >20% indicates high-grade tumor with poor prognosis.
- Somatostatin analogues improve PFS but not OS in advanced NETs.
- Telotristat ethyl is first-line for refractory carcinoid diarrhea.
- Everolimus is standard for extrapancreatic NETs with Ki-67 >55%.